# War Room Findings

Overnight research results compiled by isolated cron jobs.  
Morning briefing reads this file to assemble intel section.

---

## 2026-02-05 - Competitor Intelligence

**MiMedx - Major Partnership Announcement (Feb 4, 2026)**
- Entered exclusive distribution agreement with Summit Products Group
- Adding 3 new 510(k)-cleared products: Hydrelix, NovaForm, G4Derm Plus
- Complements existing Surgical & Wound portfolio
- Source: Globe Newswire, announced yesterday

**MiMedx - Analyst Downgrade on CMS Confusion**
- Craig-Hallum lowered near-term volume expectations
- Expects provider confusion from CMS LCD withdrawal to pressure Q1 2026 volumes
- Forecasting single-digit sequential growth in Q1 (down from prior expectations)
- Extended timeline for anticipated market share gains
- Source: Yahoo Finance, 2 days ago

**Integra LifeSciences - Aggressive CMS Positioning**
- CEO Mojdeh Poul statement: "No other company offers this breadth of cost-effective wound reconstruction solutions"
- Positioning their diverse portfolio as uniquely aligned to CMS reimbursement changes
- Emphasizing clinical evidence and uniform reimbursement across care settings
- Competitive messaging targeting market leadership post-CMS reform

**Smith+Nephew - 2026 Growth Acceleration**
- Expects approximately 6% underlying revenue growth in 2026 (up from 5% in 2025)
- Targeting 6-7% CAGR by 2028
- December 2025 investor update following turnaround success
- Source: Reuters

**Organogenesis - Industry Visibility Push**
- Principal Partner sponsor for WCCC Driving Innovation Summit at 2026 SAWC Spring
- Promoting CYGNUS Dual (dual-layered amniotic membrane product)
- Maintaining high industry event visibility

---
